Purple Biotech Ltd. (PPBT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.56

From 52W high−86.42%

Volume159260.00

Market cap$2.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.56

From 52W high

−86.42%

Volume

159260.00

Market cap

$2.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

P/E (TTM)

—

RSI (14)

39.2

MomentumView details →

1D Return

−6.80%

YTD Return

−77.63%

SummaryUpdated Jun 1, 2026

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biotechnology company founded in Israel and headquartered in Rehovot. The company went public on NASDAQ in November 2015, originally operating under the name Kitov Pharma Ltd before rebranding to Purple Biotech in December 2020. Purple Biotech focuses on developing innovative cancer therapies designed to overcome tumor immune evasion, with a pipeline of experimental drugs currently in various phases of clinical trials targeting solid tumors including lung and pancreatic cancers.

Ask drillr about Purple Biotech Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−199.60%

ROA (TTM)

−172.90%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+72.25%

FCF YoY

+12.12%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−24.43%

EBITDA YoY

—

MomentumView details →

1D Return

−6.80%

YTD Return

−77.63%

1Y Return

−74.79%

RSI (14)

39.2

vs 50D SMA

−5.71%

vs 200D SMA

−62.51%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.70x

Quick Ratio

3.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.07

EPS Surprise

209.18%

Beats (12Q)

3/12

Next Q EPS Est

−$2.88

Avg Surprise (4Q)

−47.14%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−24.49M

Op. CF (TTM)

−7.76M

Next earningsNov 13, 2026 →

Latest newsMore news →

Purple Biotech presented new preclinical data for IM1240 at the EACR 2026 conference, highlighting its anti-tumor activity, safety, and pharmacokinetic profile.101d ago

Similar companies

CDT Equity Inc.CDT BioXcel Therapeutics, Inc.BTAI CASI Pharmaceuticals, Inc.CASI Silexion Therapeutics Ltd.SLXN Curis, Inc.CRIS Artelo Biosciences, Inc.ARTL Find similar companies →

Latest newsMore news →

Purple Biotech presented new preclinical data for IM1240 at the EACR 2026 conference, highlighting its anti-tumor activity, safety, and pharmacokinetic profile.101d ago